Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

Whole-body irradiation increases the magnitude and persistence of adoptively transferred T cells associated with tumor regression in a mouse model of prostate cancer.

Ward-Kavanagh LK, Zhu J, Cooper TK, Schell TD.

Cancer Immunol Res. 2014 Aug;2(8):777-88. doi: 10.1158/2326-6066.CIR-13-0164. Epub 2014 May 6.

2.

Protection from tumor recurrence following adoptive immunotherapy varies with host conditioning regimen despite initial regression of autochthonous murine brain tumors.

Cozza EM, Cooper TK, Budgeon LR, Christensen ND, Schell TD.

Cancer Immunol Immunother. 2015 Mar;64(3):325-36. doi: 10.1007/s00262-014-1635-7. Epub 2014 Nov 19.

3.

Repertoire enhancement with adoptively transferred female lymphocytes controls the growth of pre-implanted murine prostate cancer.

Jenq RR, Curran MA, Goldberg GL, Liu C, Allison JP, van den Brink MR.

PLoS One. 2012;7(4):e35222. doi: 10.1371/journal.pone.0035222. Epub 2012 Apr 6.

4.

Immunity to murine prostatic tumors: continuous provision of T-cell help prevents CD8 T-cell tolerance and activates tumor-infiltrating dendritic cells.

Shafer-Weaver KA, Watkins SK, Anderson MJ, Draper LJ, Malyguine A, Alvord WG, Greenberg NM, Hurwitz AA.

Cancer Res. 2009 Aug 1;69(15):6256-64. doi: 10.1158/0008-5472.CAN-08-4516. Epub 2009 Jul 21. Retraction in: Cancer Res. 2016 Apr 15;76(8):2490.

5.

Transforming growth factor-beta-mediated signaling in T lymphocytes impacts on prostate-specific immunity and early prostate tumor progression.

Diener KR, Woods AE, Manavis J, Brown MP, Hayball JD.

Lab Invest. 2009 Feb;89(2):142-51. doi: 10.1038/labinvest.2008.123. Epub 2008 Dec 15.

6.

Cell-intrinsic abrogation of TGF-β signaling delays but does not prevent dysfunction of self/tumor-specific CD8 T cells in a murine model of autochthonous prostate cancer.

Chou CK, Schietinger A, Liggitt HD, Tan X, Funk S, Freeman GJ, Ratliff TL, Greenberg NM, Greenberg PD.

J Immunol. 2012 Oct 15;189(8):3936-46. doi: 10.4049/jimmunol.1201415. Epub 2012 Sep 14.

7.

Combined anti-CD40 conditioning and well-timed immunization prolongs CD8+ T cell accumulation and control of established brain tumors.

Ryan CM, Staveley-O'Carroll K, Schell TD.

J Immunother. 2008 Nov-Dec;31(9):906-20. doi: 10.1097/CJI.0b013e318189f155.

8.

A cytomegalovirus-based vaccine expressing a single tumor-specific CD8+ T-cell epitope delays tumor growth in a murine model of prostate cancer.

Klyushnenkova EN, Kouiavskaia DV, Parkins CJ, Caposio P, Botto S, Alexander RB, Jarvis MA.

J Immunother. 2012 Jun;35(5):390-9. doi: 10.1097/CJI.0b013e3182585d50.

9.

Adoptive transfer of tumor-reactive transforming growth factor-beta-insensitive CD8+ T cells: eradication of autologous mouse prostate cancer.

Zhang Q, Yang X, Pins M, Javonovic B, Kuzel T, Kim SJ, Parijs LV, Greenberg NM, Liu V, Guo Y, Lee C.

Cancer Res. 2005 Mar 1;65(5):1761-9.

10.

[New strategy of cancer immunotherapy: irradiation or chemotherapeutics-induced lymphopenia combined with immune reconstitution and tumor vaccine].

Ma J, Wang YL, Hu HM, Fox BA, Si LS.

Zhonghua Zhong Liu Za Zhi. 2005 Aug;27(8):452-6. Chinese.

PMID:
16188138
11.

CD8+ T-cell responses rapidly select for antigen-negative tumor cells in the prostate.

Bak SP, Barnkob MS, Wittrup KD, Chen J.

Cancer Immunol Res. 2013 Dec;1(6):393-401. doi: 10.1158/2326-6066.CIR-13-0109. Epub 2013 Sep 20.

12.

Rapid tolerization of virus-activated tumor-specific CD8+ T cells in prostate tumors of TRAMP mice.

Bai A, Higham E, Eisen HN, Wittrup KD, Chen J.

Proc Natl Acad Sci U S A. 2008 Sep 2;105(35):13003-8. doi: 10.1073/pnas.0805599105. Epub 2008 Aug 22.

13.

Cyclophosphamide augments antitumor immunity: studies in an autochthonous prostate cancer model.

Wada S, Yoshimura K, Hipkiss EL, Harris TJ, Yen HR, Goldberg MV, Grosso JF, Getnet D, Demarzo AM, Netto GJ, Anders R, Pardoll DM, Drake CG.

Cancer Res. 2009 May 15;69(10):4309-18. doi: 10.1158/0008-5472.CAN-08-4102. Epub 2009 May 12.

14.

Prostate tumor microenvironment alters immune cells and prevents long-term survival in an orthotopic mouse model following flt3-ligand/CD40-ligand immunotherapy.

Ciavarra RP, Holterman DA, Brown RR, Mangiotti P, Yousefieh N, Wright GL Jr, Schellhammer PF, Glass WF, Somers KD.

J Immunother. 2004 Jan-Feb;27(1):13-26.

PMID:
14676630
15.

Defining the synergistic effects of irradiation and T-cell immunotherapy for murine intracranial tumors.

Plautz GE, Inoue M, Shu S.

Cell Immunol. 1996 Aug 1;171(2):277-84.

PMID:
8806798
16.
17.
18.

Blockade of myeloid-derived suppressor cells after induction of lymphopenia improves adoptive T cell therapy in a murine model of melanoma.

Kodumudi KN, Weber A, Sarnaik AA, Pilon-Thomas S.

J Immunol. 2012 Dec 1;189(11):5147-54. doi: 10.4049/jimmunol.1200274. Epub 2012 Oct 24.

19.

Potent immunotherapy against well-established thymoma using adoptively transferred transgene IL-6-engineered dendritic cell-stimulated CD8+ T-cells with prolonged survival and enhanced cytotoxicity.

Kalyanasundaram Bhanumathy K, Zhang B, Xie Y, Xu A, Tan X, Xiang J.

J Gene Med. 2015 Aug-Sep;17(8-9):153-60. doi: 10.1002/jgm.2836.

PMID:
26212685
20.

Adoptive transfer of Mammaglobin-A epitope specific CD8 T cells combined with a single low dose of total body irradiation eradicates breast tumors.

Lerret NM, Rogozinska M, Jaramillo A, Marzo AL.

PLoS One. 2012;7(7):e41240. doi: 10.1371/journal.pone.0041240. Epub 2012 Jul 20.

Supplemental Content

Support Center